← Back to patent-cliff list
Ipratropium bromide/Albuterol sulfate
Tier C — Watch / tradeIpratropium bromide/Albuterol sulfate
Boehringer Ingelheim International Gmbh
Originator
1995
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mAChRs, ADRB2
Brand：Combivent
Indications (approved)：Asthma, Bronchospasm, Chronic obstructive pulmonary disease
Regional status
US
Withdrawn
EU
Approved
1995-01-01
China
Approved
2006-04-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ipratropium bromide/Albuterol sulfate?
Approved indications include: Asthma, Bronchospasm, Chronic obstructive pulmonary disease.
When does the Ipratropium bromide/Albuterol sulfate patent expire?
No public expiry year is available for Ipratropium bromide/Albuterol sulfate yet; this page updates once verified.
How do I get a quote for Ipratropium bromide/Albuterol sulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04